New Dual-Action drug trial offers hope for hepatitis b patients
NCT ID NCT07307586
Summary
This study is testing whether azvudine tablets can provide long-term control of chronic hepatitis B. It will involve 120 participants who have not had prior antiviral treatment. Researchers will monitor virus levels, liver function, and immune response over 12 months to see if this two-pronged approach—fighting the virus while boosting immunity—offers a better treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.